- Iambic Therapeutics CEO discusses $150 million IPO and AI's evolving role in drug developmentIambic Therapeutics completed a $150 million initial public offering, raising fresh capital and seeing its share price climb to about $24.50, roughly a 50% increase from earlier in the week. CEO T…
- City Therapeutics raises $200 million in IPO to fund next-gen RNAi programsCity Therapeutics, a biotech focused on RNA interference, completed a $200 million initial public offering, selling about 11.1 million shares at $18 each. The proceeds will back three drug candida…